Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SYRE 
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: SYRE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $53.58
1 Year Target Price $53.58
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.41% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.20B USD | Price to earnings Ratio - | 1Y Target Price 53.58 |
Price to earnings Ratio - | 1Y Target Price 53.58 | ||
Volume (30-day avg) 11 | Beta 3.17 | 52 Weeks Range 10.91 - 32.26 | Updated Date 12/3/2025 |
52 Weeks Range 10.91 - 32.26 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.7736 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.2% | Return on Equity (TTM) -38.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2173413900 | Price to Sales(TTM) 650.22 |
Enterprise Value 2173413900 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 77592130 | Shares Floating 67557916 |
Shares Outstanding 77592130 | Shares Floating 67557916 | ||
Percent Insiders 6.72 | Percent Institutions 84.3 |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD). Founded in 2022, it aims to deliver best-in-class efficacy and improved convenience through optimized dosing regimens and alternative routes of administration.
Core Business Areas
- Antibody Therapeutics Development: Development of novel antibody therapeutics targeting key mediators in IBD pathogenesis.
Leadership and Structure
The company is led by a team with experience in drug development and IBD. Details on specific executive names and organizational chart would be found on the company website or SEC filings.
Top Products and Market Share
Key Offerings
- SPY001: SPY001 is an anti-TL1A antibody designed to block the TL1A pathway, which is involved in IBD. Currently in clinical trials, no revenue. Competitors include Prometheus Biosciences (acquired by Merck) and other companies developing anti-TL1A therapeutics.
- SPY002: SPY002 is an anti-alpha 4 beta 7 antibody designed to block integrin u03b14u03b27. Currently in clinical trials, no revenue. Competitors include Takeda's Entyvio (vedolizumab) and other companies developing anti-integrin therapeutics.
- SPY003: SPY003 is an anti-IL-23 antibody designed to block the IL-23 pathway. Currently in clinical trials, no revenue. Competitors include Johnson & Johnson's Stelara (ustekinumab) and AbbVie's Skyrizi (risankizumab) and other companies developing anti-IL-23 therapeutics.
Market Dynamics
Industry Overview
The IBD therapeutics market is large and growing, driven by increasing prevalence and unmet needs. There is significant competition among established and emerging players.
Positioning
Spyre aims to differentiate itself through novel antibody engineering to potentially improve efficacy, convenience, and dosing regimens compared to existing therapies.
Total Addressable Market (TAM)
The global IBD market is estimated to reach tens of billions of dollars. Spyre is positioning itself to capture a share of this large market by developing improved therapies.
Upturn SWOT Analysis
Strengths
- Novel antibody engineering capabilities
- Experienced management team
- Targeting validated IBD pathways
- Pipeline of multiple clinical programs
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Competition from established players
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into additional indications
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- TAK
- MRK
- ABBV
- JNJ
Competitive Landscape
Spyre aims to compete by offering superior efficacy or convenience compared to existing therapies. Its success depends on positive clinical trial outcomes and effective commercialization.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by progress in clinical trials and pipeline development.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of products.
Recent Initiatives: Focus on advancing clinical programs for SPY001, SPY002, and SPY003.
Summary
Spyre Therapeutics is a clinical-stage biotech company with a focus on developing novel IBD therapies. The company has a promising pipeline of antibody therapeutics. However, it faces significant risks and competition. The company's success depends on the outcome of clinical trials and regulatory approvals, and effectively competing with larger more established companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.spyre.com |
Full time employees 95 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.